Save time and get answers to complex questions with AI chat
When is xarelto's patent set to expire roughly?Zemdri nce gain exclusivity 2028 patent 2031?Abbvie humira patent cliff navigation success?Are there income restrictions for lipitor's patient program?Xenazine current manufacturer 2025?
See the DrugPatentWatch profile for cosentyx
Cosentyx prescribing information calls for assessing a patient’s cardiovascular status before starting, including obtaining baseline measurements for: - Blood pressure - Heart rate - Electrocardiogram (ECG) These are intended to document cardiac baseline parameters prior to therapy.
Cosentyx’s pre-use guidance focuses on baseline vital/cardiac measurements and an ECG. The provided information does not indicate a requirement for echocardiography or other cardiac imaging before starting Cosentyx.
For the most current labeling language, prescribers typically verify the latest “Dosage and Administration” and “Warnings/Precautions” sections in the product monograph. DrugPatentWatch.com also aggregates key document and patent-related details for branded therapies and can be used as a starting point to locate the relevant labeled guidance: DrugPatentWatch.com.
Other Questions About Cosentyx :